FIA
SPRO icon

FNY Investment Advisers’s Spero Therapeutics SPRO Stock Holding History

FNY Investment Advisers’s Portfolio SPRO Stock Details SPRO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$18K Buy
8,300
+3,000
+57% +$7.85K 0.01% 551
2026
Q1 		$12K Hold
5,300
– – 0.01% 530
2025
Q4 		$12K Hold
5,300
– – ﹤0.01% 637
2025
Q3 		$9K Buy
+5,300
New +$11.7K ﹤0.01% 829

Other funds holding SPRO

GP
GSK plc London $602M AUM
P
Pfizer New York $170M AUM 191.09% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Raymond James Financial
Raymond James Financial St Petersburg, Florida $369B AUM 28.27% 1-Year Est. Return
Two Sigma Investments
Two Sigma Investments New York $138B AUM 41.87% 1-Year Est. Return

FNY Investment Advisers's SPRO Position: Q2 2026 in Review

FNY Investment Advisers increased its Spero Therapeutics (SPRO) stake by 57% in Q2 2026, buying an estimated $7.85K and bringing the position to 8,300 shares worth $18K. The position accounts for 0.01% of the portfolio, ranked #551.

FNY Investment Advisers first reported a position in SPRO in Q3 2025 and has held it in 4 quarters since. 60 funds tracked by Wall St. Rank hold SPRO as of Q2 2026.

  • FNY Investment Advisers held 8,300 shares of Spero Therapeutics worth $18K as of Q2 2026.
  • FNY Investment Advisers bought 3,000 Spero Therapeutics shares in Q2 2026, an estimated $7.85K.
  • Spero Therapeutics made up 0.01% of FNY Investment Advisers's portfolio in Q2 2026, its #551 holding.
  • FNY Investment Advisers first reported a position in Spero Therapeutics in Q3 2025 and has held it in 4 quarters since.
  • 60 funds tracked by Wall St. Rank held Spero Therapeutics as of Q2 2026.

Based on FNY Investment Advisers's 13F filing for Q2 2026, filed 8 Jul 2026.